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Background
B-cell Chronic Lymphocytic Leukemia (CLL) is the most
common leukemia diagnosed in adults in the western
world. Multiple Myeloma (MM), a plasma cell neoplasm
based in bone-marrow, comprises about 1% of all malig-
nant tumours. These are two incurable disorders with
treatments that focus on controlling the disease and
symptoms rather than eradicating it. Synthetic analogues
of Retinoic Acid (RA) are currently used extensively for
the treatment of skin disorders such as acne vulgaris
and psoriasis, as well certain forms of cancer namely
Acute Promyelocytic Leukemia. Preclinical studies have
also garnered support for their chemopreventive poten-
tial in many more cancers, especially haematological
malignancies.
The purpose of this study was to illustrate the roles of
Fenretinide (4HPR) and Acitretin in CLL and MM and
establish whether the two retinoic acid derivatives may
prove to be prospective treatments for these malignancies.
Fenretinide (4HPR) is a drug studied in a variety of can-
cers and has shown to induce apoptosis through increased
levels of Reactive Oxygen Species (ROS) and activation of
caspase-8, 9 and 3. Acitretin is currently used to treat
psoriasis but little is known about its effect on cancer.
Therefore, its mechanism of action is unknown.
Results
For the purpose of this study, 5 MM cell lines (RPMI-
8226, NCI-H929, MM1.s, KMS-BM-12, U-266) and pri-
mary cells isolated from whole blood of CLL patients
were used. 4HPR significantly decreased cell viability in
4 out of 5 MM cell lines tested at 5, 10, 20μM, whereas
Acitretin only had an effect at concentrations higher
than 50uM in 2 MM cell lines. CLL cells were highly
sensitive to 4HPR at all concentrations used, but were
only sensitive to Acitretin up until 10μM. 4HPR and
Acitretin also significantly decreased NCI-H929 and CLL
cells migration capabilities. Additionally, western blot ana-
lysis on RPMI-8226 cells showed that 4HPR and Acitretin
negatively affected the expression of the cell cycle markers
cyclin D2 and phospho-Rb, the anti-apoptosis marker
Mcl-1, and increased cleavage and therefore activation of
the pro-apoptotic marker PARP. This suggests that the
two inhibitors could affect both cell proliferation and
apoptosis.
Conclusions
Having conveyed promising cytotoxic and chemoattrac-
tant properties with both CLL and MM cells, 4HPR and
Acitretin have proven to be promising therapeutic candi-
dates for MM and CLL treatment.
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